Mumbai, May 13 Pharma major Cipla on Wednesday reported a 54.6 per cent decline in its consolidated net profit for the fourth quarter (Q4) of FY26, weighed down by an impairment charge, while revenue also witnessed a marginal drop on a year-on-year basis.
The company posted a consolidated net profit of Rs 554.64 crore in the January-March quarter, compared to Rs 1,221.84 crore reported in the corresponding quarter of the previous financial year (Q4 FY25), according to its stock exchange filing.
Revenue from operations during Q4 FY26 stood at Rs 6,541.20 crore, down 2.80 per cent compared to Rs 6,729.69 crore in the year-ago period.
At the operational level, EBITDA for the quarter fell 38 per cent to Rs 955 crore from Rs 1,537.6 crore in the same period last financial year.
EBITDA margin also contracted sharply to 14.6 per cent from 22.80 per cent on a YoY basis.
Cipla said that during the quarter and financial year ended March 31, 2026, it recorded an impairment charge of Rs 42.02 crore in respect of associates due to changes in certain business conditions and market dynamics.
Excluding the impairment impact, the company’s EBITDA for the quarter would have stood at Rs 997 crore, while EBITDA margin would have been 15.2 per cent.
Meanwhile, the Board of Directors of Cipla recommended a final dividend of Rs 13 per equity share for the financial year ended March 31, 2026.
The company said the dividend, subject to shareholder approval at the Annual General Meeting, will be paid within 30 days from the date of the AGM.
The company also announced June 5, 2026, as the record date for determining eligible shareholders for the final dividend payout.
Following the earnings announcement, Cipla shares traded higher in the market. At 1:34 PM, Cipla stock was up 3.7 per cent at Rs 1,340.70 apiece on the NSE.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor